Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
February 2015

Recent Stories of Interest

From Specialty Pharmacy News - Almost four months to the day from when a news report suggested that Walgreen Co. was looking for a buyer to purchase a majority stake in its infusion business, the company now known as Walgreens Boots Alliance Inc. has unveiled its plans to restructure. Private-equity group Madison Dearborn Partners, LLC (MDP) has agreed to purchase a majority stake in Walgreens Infusion Services. The companies did not disclose any financial information. But the Sept. 23 Reuters article that broke the news that Walgreens was seeking a buyer said that “a deal could value that division at around $1.5 billion.” Read more

The drug industry focus on specialty pharmaceuticals will continue in 2015, spurred… Read more

Earlier this month, the U.S. pharmaceutical market moved a lot closer to… Read more

The Dec. 19 FDA approval of AbbVie Inc.’s Viekira Pak (ombitasvir, paritaprevir… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

March 6, 2015
FDA OKs First Biosimilar

The FDA approved the first biosimilar product, Sandoz’s Zarxio, for the same five indications as its reference product, Amgen’s Neupogen

March 4, 2015
FDA OKs Metastatic NSCLC Use for Opdivo

FDA grants a second indication to BMS’s Opdivo for the treatment of metastatic non-small cell lung cancer; the approval comes 3 months before drug's PDUFA date. The PD-1 inhibitor was approved in December to treat metastatic melanoma

February 26, 2015
Diplomat Says It Will Acquire BioRx

Diplomat says it will acquire Cincinnati-based BioRx for $315 million, expanding the specialty pharmacy’s infusion services. BioRx, which was founded in 2004, had revenues of $227 million in 2014

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?